Polyplus-transfection Licenses ZNA™ Oligonucleotide Technology to Metabion
News Mar 04, 2010
Polyplus-transfection SA has announced that metabion GmbH, a company specialized in custom synthesis of biopolymers, has signed a non-exclusive agreement to manufacture and commercialize Polyplus-transfection's Zip Nucleic Acid (ZNA™) oligonucleotides, a new technology that increases affinity for nucleic acids.
Under the terms of the license, metabion GmbH has acquired rights to manufacture and commercialize custom ZNA oligonucleotides for research and in vitro diagnostic applications. metabion GmbH will begin commercialization on March 22nd, 2010.
Zip Nucleic Acids (ZNA™) are novel modified oligonucleotides that offer increased affinity for nucleic acids without reducing specificity. This brings several advantages: ZNAs improve the performance of molecular hybridization techniques such as PCR assays when used as primers or probes, ZNAs also increase the sensitivity of tests and the detection of mutations, in addition, ZNAs' performance compares favourably with the modified oligonucleotides available in the market today.
"We are truly delighted to sign this agreement with metabion, a well-established dynamic oligonucleotide company in Europe," said Mark Bloomfield, CEO of Polyplus-transfection. "This licensing agreement will enable more members of the life science community to access our innovative ZNA technology."
"In line with our approach to intelligently and deliberately expand our oligonucleotide custom synthesis portfolio to bring ever increasing value to our customers, we see great potential for ZNA™ modified oligonucleotides due to the inherent (chemical) advantages they offer for state-of-the-art molecular biological applications," said Dr. Regina Bichlmaier, CEO at metabion. "Combining our own and our customers´ expertise, this new technology will contribute to increase R&D flexibility and progress."
About 422 million people around the world, including more than 30 million Americans, have diabetes. Obesity is the most significant risk factor for type 2 diabetes. yet about 30 percent of obese people do not develop type 2 diabetes or other metabolic conditions. New research aims to understand on a cellular level, how this separation occurs.READ MORE
Measuring hand grip can help identify youths who could benefit from lifestyle changes, says new research. While other studies have shown that muscle weakness as measured by grip strength is a predictor of unhealthy outcomes - including cardiovascular and metabolic diseases - this is the first to do so for adolescent health over time.READ MORE